5th January 2021
USADA announced today that Scott Hisaka, 30, of Concord, Cal., an athlete in the sport of weightlifting, has accepted a four-year suspension for an anti-doping rule violation involving his possession of multiple prohibited substances. In addition to education and testing, robust anti-doping programs enable investigations stemming from various sources, including tips (Play Clean Tip Line) and whistleblowers. USADA investigations can reveal evidence about the actions of coaches, athletes, and support personnel who have engaged in, instigated, facilitated, or encouraged doping.
This type of information led USADA to discover that Hisaka made five independent purchases of products containing prohibited substances from Transformix Peptides, an online store, between October 2014 and April 2015. The products contained the prohibited substances Insulin-like Growth Factor-1 (IGF-1), Growth Hormone Release Peptide-2 (GHRP-2), GHRP-6, CJC-1295, tamoxifen, clomiphene, and letrozole.
IGF-1, GHRP-2, GHRP-6, CJC-1295 are Non-Specified Substances in the class of Peptide Hormones, Growth Factors, Related Substances, and Mimetics. Tamoxifen, clomiphene, and letrozole are Specified Substances in the class of Hormone and Metabolic Modulators. Each of the substances that Hisaka purchased is prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policy, and the International Weightlifting Federation Anti-Doping Policy, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.
Hisaka’s four-year period of ineligibility began on December 15, 2020, the date on which he accepted the sanction. In addition, Hisaka’s competitive results on and subsequent to October 31, 2014, the date on which he first purchased prohibited substances, have been disqualified, including forfeiture of any medals, points and prizes.a